500
His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.
 His PD: Subject; His: Subject.Gender; pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily: Treatment; via nasogastric tube: Treatment; PD: Treatment.Disorder; pramipexole: Treatment.Drug; entacapone: Treatment.Drug; levodopa: Treatment.Drug; carbidopa: Treatment.Drug; 100 mg/25: Treatment.Dosage; mg/25 mg: Treatment.Dosage; 1.5 tablets: Treatment.Dosage; 4 times daily: Treatment.Freq; nasogastric tube: Treatment.Route; pramipexole: Combination.Drug; entacapone: Combination.Drug; levodopa: Combination.Drug; carbidopa: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 His PD: Subject; His: Subject.Gender; pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily: Treatment; via nasogastric tube: Treatment; PD: Treatment.Disorder; pramipexole: Treatment.Drug; entacapone: Treatment.Drug; levodopa: Treatment.Drug; carbidopa: Treatment.Drug; 100 mg/25: Treatment.Dosage; mg/25 mg: Treatment.Dosage; 1.5 tablets: Treatment.Dosage; 4 times daily: Treatment.Freq; nasogastric tube: Treatment.Route; pramipexole: Combination.Drug; entacapone: Combination.Drug; levodopa: Combination.Drug; carbidopa: Combination.Drug